The Anti-Diabetes Drugs market in Montenegro has been showing steady growth in recent years.
Customer preferences: Montenegrin customers have been increasingly opting for anti-diabetes drugs that are more effective and have fewer side effects. As a result, there has been a shift towards newer drugs such as GLP-1 receptor agonists and SGLT2 inhibitors. Additionally, there has been a growing demand for personalized treatment plans that take into account the specific needs of each patient.
Trends in the market: One of the key trends in the Montenegrin Anti-Diabetes Drugs market is the increasing focus on preventive measures. With a growing awareness of the risks associated with diabetes, there has been a greater emphasis on early diagnosis and intervention. This has led to an increased demand for drugs that can help prevent the onset of diabetes or delay its progression. Another trend that has been observed is the growing popularity of online pharmacies, which offer a convenient and cost-effective way for customers to purchase their medication.
Local special circumstances: Montenegro has a relatively high prevalence of diabetes, with an estimated 12% of the population affected by the disease. This has led to a significant demand for anti-diabetes drugs in the country. Additionally, the Montenegrin healthcare system is largely publicly funded, which means that the government plays a key role in regulating the market and influencing customer preferences.
Underlying macroeconomic factors: The Montenegrin economy has been growing steadily in recent years, which has led to an increase in disposable incomes and a greater willingness to spend on healthcare. Additionally, the country's accession to the European Union has led to greater regulatory harmonization and increased competition in the market. However, there are still challenges to be addressed, including the high cost of some of the newer anti-diabetes drugs and the need for greater awareness and education around the disease.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
